Methods for determining genetic predisposition to autoimmune diseases by genotyping apoptotic genes
Patent 6162604 Issued on December 19, 2000. Estimated Expiration Date: April 1, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
Genetic markers associated with programmed cell death were characterized and their extent of polymorphism in normal populations was determined allowing for a method for determining genetic predisposition to SLE and other autoimmune diseases by genotyping. The allelic distribution of these gene markers in a large Mexican American SLE cohort and ethnically matched controls was determined. The results were that bcl-2, Fas-L, and IL-10 loci showed significantly different allelic distribution in SLE patients compared with controls, indicating an association between these gens and SLE. The method allows for determining the presence of these alleles. Alone, the presence of each of these alleles is associated with a moderate increase in SLE risk, while the occurrence of these alles together increases the odds of developing SLE by more than 40-fold.
Tsujimoto et al., "DNA rearrangements in human follicular lymphoma can involve the 5' or 3' region of the bcl-2 gene", Proceedings of the National Academy of Sciences, USA, vol. 84, pp. 1329-1331, Mar. 1987
Platzer et al., "Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs", International Immunology, vol. 7 (4), pp. 517-523, Dec. 1994
Alderson et al., "Fas ligand Mediates Activation-induced cell death in human T lymphocytes", Journal of Esperimental Medicine, vol. 181, pp. 71-77, Jan. 1995
Harley et al., "Lupus and Interleukin 10", Journal of Rheumatology, vol. 24 (12), pp. 2273-2275, 1997
Aringer et al., "High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes of patients with systemic lupus erythematosus", Arthritis and Rheumatism, vol. 37 (10), pp. 1423-1430, Oct. 1994
Donner et al., "CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to Type 1 Diabetes Mellitus", Journal of clinical endiocrinology and metabolism, vol. 82 (1), pp. 143-146, 1997
Huang et al., "Identification and characterization of polymorphism in the promoter region of the human Apo-1/Fas (CD95) gene", Molecular Immunolgy, vol. 34 (8-9), pp. 577-582, 1997
Eskdale, et al., Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus, Tissue Antigens 49:635-639 (1997)
Polymeropoulos, et al., Tetranucleotide repeat polymorphism at the human c-fes/fps proto-oncogene (FES), Nucleic Acids Research 19(14):4018 (1991)
Tan et al., The 1982 Revised Criteria For The Classification of Systemic Lupus Erythematosus, Arthritis and Rheumatism 25(11):1271-1277 (1982)
Turner, et al., An Investigation of Polymorphism in the Interleukin-10 Gene Promoter, European Journal of Immunogenetics 24:1-8 (1997